The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror.Over the past five years, Eli Lilly (LLY 1.43%) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incredible commercial success.But Lilly isn't done just yet. Recent clinical developments may set the stage for further stock-market gains, and potentially allow the drugmaker to maintain that momentum through ...

Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.Eli Lilly (LLY -3.77%) recently released top-line results from a head-to-head trial of its oral GLP-1 pill, orforglipron, compared to Novo Nordisk's (NVO -4.54%) oral version of Wegovy (semaglutide), and claimed superiority in treating type 2 diabetes. According to the press release, "In key secondary endpoints, orforglipron was also superior to oral semaglutide for weight loss." Neither pill is yet available for ...

Amid the ongoing United States stock market rally, several equities have experienced increased buying pressure, pushing their valuations closer to the coveted $1 trillion market capitalization mark.With the new year on the horizon, the following two U.S. companies are increasingly showing the potential to break into the trillion-dollar club, driven by ambitious fundamentals.Oracle (NASDAQ: ORCL)At roughly $867 billion in market value, Oracle (NASDAQ: ORCL) is only 15% away from the trillion-dollar threshold ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Dive Brief: Eli Lilly said it will build a $6.5 billion factory in Houston focused on manufacturing the company’s first obesity pill and other small molecule medicines. The 236-acre site will produce active pharmaceutical ingredients, among them orforglipron, a small, oral GLP-1 receptor agonist, according to a news release. The molecule agonist is up f ...

Eli Lilly has revealed it is to build an active pharmaceutical product (API) facility in Texas, US, a week after revealing Virginia as the first site in its $27bn US manufacturing drive. The $6.5bn manufacturing facility will produce Eli Lilly’s array of small molecule therapeutics – chief among which will be orforglipron, the drugmaker’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) hopeful in obesity treatment. Lilly’s CEO David Ricks said: "Our new Houston site will enhance Lilly's ability t ...

Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new facility will produce APIs for small-molecule medicines, including those targeting oncology, cardiometabolic health, immunology and neuroscience. It will create 615 permanent jobs, including positions for scientists, engineers, lab technicians and operations personnel. The construction phase will generate 4,000 jo ...

投资计划 - 公司宣布投资65亿美元在美国德克萨斯州休斯敦建设全新生产设施以扩大其小分子药物产能 重点用于生产实验性口服减肥药orforglipron [1] - 这是公司今年宣布的第二项重大投资计划 此前2月已宣布计划斥资至少270亿美元在美国新建四家制造工厂 [1] - 自2020年以来公司在美国国内生产领域的累计投资已达230亿美元 其余两家工厂选址将在今年公布 预计未来五年内四家工厂全部投入运营 [1] 产能扩张背景 - 美国减肥药需求激增 公司与竞争对手诺和诺德的GLP-1类每周注射药物面临供应紧张局面 [1] - 口服剂型orforglipron被视为公司维持市场主导地位的关键产品 [1] - 新工厂将大幅提升orforglipron规模化生产能力 帮助满足全球数千万肥胖症及2型糖尿病患者治疗需求 [1] 产品优势 - 相比注射剂型 口服药物无需进食或饮水限制 服用更加便利 [1] - 口服剂型不仅能解决产能不足问题 还将进一步拓宽潜在患者群体 [1] - 小分子药物通常以口服片剂形式出现 对患者使用更方便 更易于大规模生产 制造成本相对更低 [2] 战略考量 - 公司扩大在美国产能布局不仅为满足市场需求 也为降低政策不确定性带来的供应链风险 [2] - 此举是对美国总统特朗普最新关税政策威胁的积极回应 特朗普曾表示可能对进口到美国的药品征收关税以推动制药企业将生产环节迁回美国 [2] - 过去十年美国本土药品制造业规模显著萎缩 [2] 生产范围与就业影响 - 休斯敦新工厂将主要生产orforglipron以及其他针对心脏代谢健康、肿瘤学、免疫学和神经科学等领域的小分子药物 [2] - 该项目将为休斯敦地区带来615个全职岗位 包括工程师、科学家、运营人员和实验室技术人员 [2] - 同时在建设过程中创造4000个建筑相关工作岗位 [2]

Key TakeawaysFord (F) has expanded a recall to 4,632 Expedition and Navigator SUVs from the 2020 model year due to a battery junction box circuit board short risk, with two underhood fires reported, though no stop-driving instructions have been issued.Disney+ (DIS) is set to implement another price hike in October, with the ad-supported plan increasing by $2 to $11.99 and the premium no-ads plan rising by $3, reflecting ongoing "streamflation" in the digital entertainment sector.Federal Reserve Chair Jerome ...

Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday. ...

Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill. It is the second in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020. Eli Lilly ...